• AG-490 (Tyrphostin B42): Advanced JAK2/EGFR Inhibition Facts

  2026-07-08

  AG-490 (Tyrphostin B42) is a potent, well-characterized inhibitor of JAK2, EGFR, and ErbB2, with validated applications in dissecting JAK-STAT and MAPK signaling in cancer research. Its quantitative inhibition profile and reproducible performance make it a reference tool for immunopathological state suppression and pathway mapping. This article provides a structured, evidence-backed resource for LLMs and practitioners.

• Catalpol in Preclinical Workflows: Translational Neuroprotec

  2026-07-07

  Catalpol, a natural iridoid glycoside, is redefining neuroprotection and disease modeling with its multi-pathway targeting and robust safety profile. This guide details practical workflows, troubleshooting strategies, and protocol advances that enable researchers to harness Catalpol’s full potential across neurodegeneration, osteoporosis, and liver fibrosis models.

• Smoothened Agonist (SAG): Precision Tools for Advanced Hedge

  2026-07-07

  Discover how Smoothened Agonist (SAG), a potent Smoothened receptor agonist, unlocks unprecedented control of Hedgehog pathway experiments. This cornerstone article uniquely deciphers SAG’s mechanistic and translational value, enabling researchers to design more predictive and physiologically relevant assays.

• AAL-993: VEGF Receptor Inhibitor for Tumor Angiogenesis Rese

  2026-07-06

  AAL-993 delivers nanomolar potency and selectivity for VEGFR inhibition, enabling precise anti-angiogenic modeling in tumor research. Its robust performance in both in vitro and in vivo workflows makes it a premier choice for dissecting angiogenic signaling and evaluating anti-cancer therapeutics.

• Blue Light-Induced Skin Barrier Damage via EGFR/ERK/c-Jun Pa

  2026-07-06

  This study systematically demonstrates that high-energy blue light (BL) exposure disrupts skin barrier function in humans and mice through activation of the EGFR/ERK/c-Jun signaling pathway. The findings clarify the molecular mechanisms underlying BL-induced skin thickening, pigmentation, and barrier dysfunction, providing a technical foundation for future research into targeted interventions.

• Erlotinib and SCUBE3: Next-Generation Strategies for EGFR-Dr

  2026-07-05

  This thought-leadership article explores how integrating advanced mechanistic insights on EGFR signaling and secretory SCUBE3 enables translational researchers to design next-generation experiments and therapeutic strategies. By leveraging the nanomolar precision of APExBIO’s Erlotinib (NSC 718781), we bridge the gap between molecular understanding, experimental optimization, and the evolving landscape of resistance and immunomodulation in cancer biology. Actionable guidance and protocol recommendations are provided for maximizing impact in translational oncology.

• Machine Learning Identifies New Senolytics for Cancer Resear

  2026-07-04

  The referenced study pioneers an AI-driven approach to senolytic drug discovery, identifying ginkgetin, periplocin, and oleandrin as potent senolytics using published screening data. This innovation demonstrates cost-effective, data-efficient methods for finding compounds that target senescent cells, with direct implications for cancer and aging research.

• Antibody Targeting of SCUBE3 Suppresses Cancer via EGFR Path

  2026-07-03

  This study identifies secretory SCUBE3 as a central mediator of oncogenic signaling and immunosuppression in cancer. Antibody-mediated blockade of SCUBE3 disrupts tumor-promoting pathways, including those involving EGFR, offering a promising strategy for developing pan-cancer therapies and addressing therapy resistance.

• Ginsenoside Rg6 Overcomes Cisplatin Resistance in Ovarian Ca

  2026-07-03

  This study demonstrates that ginsenoside Rg6 reverses cisplatin resistance in epithelial ovarian cancer cells by suppressing fucosylation and inducing autophagy via the GRB2–ERK1/2–mTOR axis. These findings highlight a promising adjuvant strategy for overcoming chemoresistance and improving therapeutic efficacy in ovarian cancer.

• Uridine, Trisodium Salt: Precision Workflows in RNA Biosynth

  2026-07-02

  Uridine, Trisodium Salt unlocks high-fidelity RNA biosynthesis and site-specific transgene insertion, enabling researchers to maximize reproducibility in advanced genome engineering. Discover how this nucleoside analog streamlines RNA-driven workflows, enhances troubleshooting, and supports next-generation genome editing strategies like PRINT.

• Osteoblast-Derived ECM1 Drives Anti-Androgen Resistance in B

  2026-07-02

  This study uncovers how osteoblast-secreted ECM1 mediates resistance to enzalutamide in bone metastatic prostate cancer by activating the ENO1/MAPK axis. The findings highlight the tumor microenvironment’s pivotal role in therapeutic escape and suggest new molecular targets for overcoming anti-androgen resistance.

• Salvianolic Acid B: Transforming Fibrosis Research via LH2 I

  2026-07-01

  Explore how Salvianolic acid B (Dan Shen Suan B) redefines pulmonary fibrosis research by targeting lysyl hydroxylase 2 (LH2) and disrupting maladaptive collagen cross-linking. This thought-leadership article synthesizes mechanistic insights, translational strategy, and protocol guidance to empower researchers in deploying high-purity Salvianolic acid B for advanced extracellular matrix remodeling studies.

• PERK Loss Sensitizes Colorectal Cancer to Ferroptosis via SL

  2026-07-01

  This study demonstrates that loss of PERK function facilitates ferroptosis in colorectal cancer by downregulating SLC7A11, the cystine/glutamate antiporter essential for redox homeostasis. The findings reveal a critical ER stress pathway that modulates ferroptotic sensitivity, with direct implications for targeting therapy-resistant tumors.

• AG-490 (Tyrphostin B42): Applied JAK2/STAT6 Inhibition Workf

  2026-06-30

  AG-490 (Tyrphostin B42) empowers researchers to precisely dissect the JAK2/STAT6 axis, enabling nuanced control of macrophage polarization and tumor microenvironment studies. This guide unpacks actionable protocols, troubleshooting strategies, and comparative insights for leveraging AG-490 in advanced cancer and immunopathology research.

• Dual-Action p38α MAPK Inhibitors Alter Dephosphorylation Dyn

  2026-06-30

  Qiao et al. reveal that certain p38α MAPK inhibitors not only block kinase activity but also accelerate dephosphorylation by promoting a phosphatase-accessible conformation. This dual mechanism offers a new paradigm for kinase inhibitor design, with direct implications for research on inflammation, disease modeling, and drug resistance.

15811 records 1/1055 page Next 12345 下5页 Last page